Table 2.
Summary of the 35 patients with GBS that were reported in the literature
| Category | Number of cases | |
|---|---|---|
| Total number of patients | 35 | |
| Gender | Males | 22 |
| Females | 13 | |
| Presentation | Progressive weakness | 19 |
| Not mentioned | 9 | |
| Other | 7 | |
| Nasopharyngeal SARS-CoV-2 PCR test | Positive | 17 |
| Negative | 5 | |
| Not mentioned/not done | 13 | |
| Serology test of SARS-CoV-2 | Positive | 12 |
| Negative | 0 | |
| Not done | 23 | |
| GBS variant | AMAN | 6 |
| AIDP | 9 | |
| MFS | 3 | |
| MFS with PRES | 1 | |
| Inexcitable | 1 | |
| Not mentioned/NCS not done | 15 | |
| Treatment | IVIG one dose | 19 |
| IVIG two doses | 2 | |
| Steroids | 4 | |
| Underwent plasma exchange | 2 | |
| Not mentioned | 13 | |
GBS Guillain-Barré syndrome, PCR polymerase chain reaction, IVIG intravenous immunoglobulins, AIDP acute inflammatory demyelinating polyradiculoneuropathy, AMAN acute motor axonal neuropathy, MFS Miller Fisher syndrome, PRES posterior reversible encephalopathy syndrome, NCS nerve conduction study